The forecasted import values of penicillins or streptomycins in dosage forms to France show a gradual decline from $116.26 million in 2024 to $107.21 million in 2028. In 2023, this value stood at $118.6 million, indicating a steady decrease in exports over the forecasted period. The year-on-year variations indicate consistent negative trends, with a compound annual growth rate (CAGR) reflecting an average decline over the five-year period.

Trends to watch for in the future include:

Potential regulatory changes affecting pharmaceutical imports.
Shifts in global supply chains impacting the availability of penicillins and streptomycins.
Developments in alternative treatments that may affect demand.